Your browser doesn't support javascript.
loading
Platinum-Pemetrexed Chemotherapy for Recurrent Ovarian Cancer (ROC): A Single Center Experience.
Joel, Anjana; John, George; Daniel, Sherin; Thomas, Vinotha; Sebastian, Ajit; Ramireddy, Jeba Karunya; Chandramohan, Anuradha; John, Ajoy Oommen; Georgy, Josh Thomas; Chacko, Raju Titus; Yadav, Bijesh; Singh, Ashish.
Affiliation
  • Joel A; Department of Medical Oncology, CMC Vellore, Vellore, India.
  • John G; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
  • Daniel S; Department of Pathology, CMC Vellore, Vellore, India.
  • Thomas V; Department of Gynecologic Oncology, CMC Vellore, Vellore, India.
  • Sebastian A; Department of Gynecologic Oncology, CMC Vellore, Vellore, India.
  • Ramireddy JK; Department of Radiotherapy, CMC Vellore, Vellore, India.
  • Chandramohan A; Department of Radiology, CMC Vellore, Vellore, India.
  • John AO; Department of Medical Oncology, CMC Vellore, Vellore, India.
  • Georgy JT; Department of Medical Oncology, CMC Vellore, Vellore, India.
  • Chacko RT; Department of Medical Oncology, CMC Vellore, Vellore, India.
  • Yadav B; Department of Biostatistics, CMC Vellore, Vellore, India.
  • Singh A; Department of Medical Oncology, CMC Vellore, Vellore, India.
Cancer Invest ; 39(10): 893-901, 2021 Nov.
Article in En | MEDLINE | ID: mdl-34486892
In this retrospective analysis of 36 patients with recurrent ovarian cancer (ROC) treated with platinum pemetrexed doublet ± bevacizumab, the median age was 54.5 years (47-60) and 33 (91.7%) had serous histology. The overall response rate [ORR = complete (CR)+partial (PR) response] was 83.3%. At a median follow-up of 16 months, the median PFS was 13.8 months (95% CI: 10.849-20.580) and median OS 30.6 months, (95% CI: 21.46 months-NR). The incidence of Grade 3/4 anemia, thrombocytopenia, neutropenia and non-hematological toxicity was 19.4%, 3.9%, 16.6%, and 8.3%. Platinum pemetrexed chemotherapy in ROC is safe and effective treatment option.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Carboplatin / Pemetrexed / Neoplasm Recurrence, Local Type of study: Observational_studies / Risk_factors_studies Limits: Female / Humans / Middle aged Language: En Journal: Cancer Invest Year: 2021 Document type: Article Affiliation country: India Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Carboplatin / Pemetrexed / Neoplasm Recurrence, Local Type of study: Observational_studies / Risk_factors_studies Limits: Female / Humans / Middle aged Language: En Journal: Cancer Invest Year: 2021 Document type: Article Affiliation country: India Country of publication: United kingdom